Get the Stockscreener App
6.66
20.07%
-1.6725
Reshape Lifesciences Inc stock is traded at $6.66, with a volume of 324.92K.
It is down -20.07% in the last 24 hours and down -22.15% over the past month.
Reshape Lifesciences Inc is a medical device company focused on technologies to treat obesity and metabolic diseases. The company's current portfolio includes the LAP-BAND, an Adjustable Gastric Banding System, ReShapeCare virtual health coaching program, ReShape Market Place, including ReShape Optimize a supplemental multivitamin, the Obalon Balloon System, the first and only swallowable gas-filled balloon system, and the Diabetes Bloc-Stim Neuromodulation, a technology under development as a new treatment for type 2 diabetes mellitus. Geographically, the company operates in the United States, Australia, Europe, and the Rest of world, and the majority of its revenue is generated from the United States.
See More
Previous Close:
$8.3325
Open:
$7.12
24h Volume:
324.92K
Relative Volume:
0.49
Market Cap:
$4.74M
Revenue:
$9.81M
Net Income/Loss:
$-26.16M
P/E Ratio:
-0.1718
EPS:
-38.77
Net Cash Flow:
$-17.45M
1W Performance:
-36.57%
1M Performance:
-22.15%
6M Performance:
-95.24%
1Y Performance:
-97.26%
1-Day Range:
$5.53
$7.30
1-Week Range:
$5.53
$11.65
52-Week Range:
$5.53
$725.00
Reshape Lifesciences Inc Stock (RSLS) Company Profile
Name
Reshape Lifesciences Inc
Sector
Industry
Phone
949-429-6680
Address
1001 CALLE AMANECER, SAN CLEMENTE
Compare RSLS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RSLS
Reshape Lifesciences Inc
|
6.66 | 4.74M | 9.81M | -26.16M | -17.45M | -38.77 |
|
ABT
Abbott Laboratories
|
133.24 | 231.09B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
102.86 | 155.24B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
380.92 | 144.54B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
83.48 | 108.82B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
73.68 | 44.31B | 5.54B | 4.18B | 623.10M | 7.00 |
Reshape Lifesciences Inc Stock (RSLS) Latest News
Reshape Lifesciences Inc Files For Mixed Shelf Offering Of Up To $50 MillionSEC Filing - marketscreener.com
ReShape Lifesciences Announces Reverse Stock Split - TipRanks
ReShape Lifesciences announces 1-for-25 reverse stock split By Investing.com - Investing.com Canada
ReShape Lifesciences (RSLS) Announces 1-for-25 Reverse Stock Split - GuruFocus
ReShape Lifesciences Announces 1-for-25 Reverse Stock Split - The Manila Times
ReShape Lifesciences announces 1-for-25 reverse stock split - Investing.com
ReShape Lifesciences Inc. Announces 1-for-25 Reverse Stock Split Effective May 9, 2025 - Nasdaq
Stocktwits Spotlight: NRx, CVS, ReShape Lead Weekly Jump In Health Care Stock Chatter - MSN
STOCKHOLDER ALERT: The M&A Class Action Firm Continues Its Investigation Into The MergerALBT, NDOI, DNB, RSLS - The Malaysian Reserve
ReShape Lifesciences (RSLS) Secures Patent for Innovative Intrag - GuruFocus
ReShape Lifesciences (RSLS) Showcases Promising Diabetes Device at Neuromodulation Event | RSLS Stock News - GuruFocus
ReShape Lifesciences® Unveils Innovative Diabetes Neuromodulation Device Demonstrating Safe Glucose Modulation at Minnesota Neuromodulation Symposium - Nasdaq
ReShape Lifesciences® Presents Pre-clinical Data on Its - GlobeNewswire
Breakthrough Diabetes Treatment: New Neuromodulation Device Eliminates Need for Insulin Injections - Stock Titan
$HAREHOLDER ALERT: The M&A Class Action Firm Continues To Investigate The Merger – ALBT, NDOI, DNB, RSLS - GlobeNewswire Inc.
The Psychology of ReShape Lifesciences Inc Inc. (RSLS) Price Performance: Understanding Market Sentiment - investchronicle.com
There is no way ReShape Lifesciences Inc (RSLS) can keep these numbers up - Sete News
Market Resilience: ReShape Lifesciences Inc (RSLS) Finishes Weak at 0.36, Down -0.85 - DWinneX
Checking in on ReShape Lifesciences Inc (RSLS) after recent insiders movement - knoxdaily.com
Closing Figures Unveiled: ReShape Lifesciences Inc (RSLS) Drop -12.17, Closes at 0.39 - DWinneX
ReShape Lifesciences amends asset purchase terms with Ninjour By Investing.com - Investing.com Nigeria
ReShape Lifesciences secures patent for intragastric balloon By Investing.com - Investing.com Canada
ReShape Lifesciences amends asset purchase terms with Ninjour - Investing.com
ReShape Lifesciences (RSLS) Advances with New Patent for Intraga - GuruFocus
ReShape Lifesciences® Receives Notice of Allowance for Key U.S. Patent Related to an Intragastric Balloon System - The Manila Times
Revolutionary Weight Loss Tech: ReShape's New Patent Protects Self-Deflating Gastric Balloon Innovation - Stock Titan
ReShape Lifesciences Inc (RSLS)’s highs and lows: A closer look at its stock price fluctuations - uspostnews.com
Press Release Distribution & PR Platform - ACCESS Newswire
ReShape Lifesciences® Reports Year Ended December 31, 2024 Financial Results and Provides Corporate Update - The Globe and Mail
Insider Sale Alert: ReShape Lifesciences Inc [RSLS] – Is it Time to sell? - knoxdaily.com
ReShape Lifesciences skyrockets after receiving U.S. patent for diabetes neuromodulation technology - MSN
ReShape Lifesciences Ignites Retail Frenzy As Stock Soars On US Patent For Diabetes Neuromodulation System - Asianet Newsable
ReShape Shares Soar After USPTO's Notice of Allowance for Diabetes Neuromodulation Patent - marketscreener.com
ReShape Lifesciences secures patent for diabetes treatment By Investing.com - Investing.com South Africa
ReShape Lifesciences Gets USPTO's Notice of Allowance for Diabetes Neuromodulation Patent - marketscreener.com
ReShape Lifesciences (RSLS) Gains on Diabetes Neuromodulation Patent News - GuruFocus
ReShape Lifesciences secures patent for diabetes treatment - Investing.com
ReShape Lifesciences® Receives Notice of Allowance for Additional U.S. Patent Related to Its Proprietary Diabetes Neuromodulation Technology - The Manila Times
ReShape Lifesciences® Secures Patent for Innovative Vagal Neuromodulation Device to Treat Type 2 Diabetes with Enhanced Energy Efficiency - Nasdaq
ReShape Lifesciences® Receives Notice of Allowance for - GlobeNewswire
ReShape Lifesciences, Allarity, Exact Sciences, CVS, AbbVie: 5 Health Care Stocks That Led Retail Message Growth Last Week - MSN
Why Did ReShape Lifesciences Plunge 11.04%? Earnings Miss, Bearish Sentiment - AInvest
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Earnings call transcript: ReShape Lifesciences Q1 2024 sees cost cuts amid revenue drop - Investing.com UK
Reshape Lifesciences Stock Price, Quotes and Forecasts | NASDAQ:RSLS - Benzinga
ReShape Lifesciences Reports 2024 Financial Results and Strategic Updates - TipRanks
Earnings call transcript: ReShape Lifesciences Q1 2024 sees cost cuts amid revenue drop By Investing.com - Investing.com South Africa
Crude Oil Falls Over 4%; Keros Therapeutics Shares Jump - Benzinga
ReShape Lifesciences Shares Surge 82.2% After Partnership Announcement - AInvest
Dow Tumbles Over 800 Points; US Inflation Rate Falls In March - Benzinga
Penny Stock ReShape To Distribute FDA-Cleared Neuromuscular Device In US - Benzinga
Reshape Lifesciences Inc Stock (RSLS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.11%
0.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):